☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of the registrant’s ordinary shares, $0.01 par value, outstanding as of ~~October 20, 2023~~April 26, 2024 was ~~166,881,286~~169,221,311 shares.

This document contains and incorporates by reference “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, these statements can be identified by the use of forward-looking terminology such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “continue,” “believe,” “plan,” “estimate,” “intend,” or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. ~~Forward‑looking~~Forward-looking statements in this Quarterly Report on Form 10-Q (this “Form 10-Q”) may include, without limitation, statements regarding:

Actual results might differ materially from those expressed or implied by these forward-looking statements because these forward-looking statements are subject to risks, assumptions and uncertainties. In light of these risks, assumptions and uncertainties, the forward-looking expectations discussed in this Form 10-Q might not occur. You are cautioned not to place undue reliance on the forward-looking statements in this Form 10-Q, which speak only as of the date of this Form 10-Q. All subsequent written and oral forward-looking statements concerning the matters addressed in this Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For information about the risks, assumptions and uncertainties of our business, see “Part I, Item 1A—Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2022,~~2023, filed

with the United States (“U.S.”) Securities and Exchange Commission (the “SEC”) on February ~~16, 2023, as amended by our Amendment No. 1 to Annual Report on Form 10-K/A, filed with the SEC on April 26, 2023~~21, 2024 (our “Annual Report”), “Part II, Item 1A—Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (our “Q1 Quarterly Report”) and “Part II, Item 1A—Risk Factors” in this Form 10-Q..

This Form 10-Q may include data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that any industry publications and third-party research, surveys and studies from which data is included in this Form 10-Q are reliable, we have not independently verified any such data. This Form 10-Q may also include data based on our own internal estimates and research. Our internal estimates and research have not been verified by any independent source and are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Part I, Item 1A—Risk Factors” in our Annual ~~Report, “Part II, Item 1A—Risk Factors” in our Q1 Quarterly Report and “Part II, Item 1A—Risk Factors” in this Form 10-Q.~~Report. These and other factors could cause our results to differ materially from those expressed or implied in this Form 10-Q.

Alkermes plc is a ~~fully-integrated,~~ global biopharmaceutical company that ~~applies its scientific expertise and proprietary technologies~~seeks to ~~research,~~ develop ~~and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs~~innovative medicines in the field of ~~patients in major therapeutic areas.~~neuroscience. We have a portfolio of proprietary commercial products ~~focused on~~for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of ~~product~~clinical and preclinical candidates in development for neurological disorders, ~~and cancer.~~including narcolepsy. Use of terms such as “us,” “we,” “our,” “Alkermes” or the “Company” in this Form 10-Q is meant to refer to Alkermes plc and its consolidated subsidiaries. Except as otherwise suggested by the context, (a) references to “products” or “our products” in this Form 10-Q include our marketed products, marketed products using our proprietary technologies, our licensed products, our product candidates and product candidates using our proprietary technologies, (b) references to the “biopharmaceutical industry” in this Form 10-Q are intended to include reference to the “biotechnology industry” and/or the “pharmaceutical industry” and (c) references to “licensees” in this Form 10-Q are used interchangeably with references to “partners.”

We are the owner of various U.S. federal trademark registrations (“®”) and other trademarks (“TM”), including ALKERMES®, ARISTADA®, ARISTADA INITIO®, LinkeRx®, LYBALVI®, NanoCrystal® and VIVITROL®.

The following are trademarks of the respective companies listed: ~~AMPYRA~~®~~—Acorda Therapeutics, Inc.; ANJESO~~®~~—Baudax Bio, Inc.;~~ BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA®, ~~XEPLION~~®, and ~~RISPERDAL CONSTA~~XEPLION®—Johnson & Johnson or its affiliated companies; ~~CABENUVA~~®~~—ViiV Healthcare UK (No.3) Limited; KEYTRUDA~~®~~—Merck Sharp & Dohme Corp.;~~ and VUMERITY®—Biogen MA Inc. (together with its affiliates, “Biogen”). Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.~~

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

4.5. INVESTMENTS

Investments consisted of the following (in thousands):


			Gross Unrealized												Gross Unrealized
					Losses												Losses
	Amortized				Less than			Greater than			Estimated		Amortized				Less than			Greater than			Estimated
September 30, 2023	Cost		Gains		One Year			One Year			Fair Value
March 31, 2024													Cost		Gains		One Year			One Year			Fair Value
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities													$	214,958	$	227	$	(77	)	$	(444	)	$	214,664
Corporate debt securities														109,691		290		(25	)		(325	)		109,631
Total short-term investments														324,649		517		(102	)		(769	)		324,295
Long-term investments:
Available-for-sale securities:
U.S. government and agency debt securities														29,446		—		(81	)		(207	)		29,158
Corporate debt securities														32,104		—		(49	)		(251	)		31,804
														61,550		—		(130	)		(458	)		60,962
Held-to-maturity securities:
Certificates of deposit														1,820		—		—			—			1,820
Total long-term investments														63,370		—		(130	)		(458	)		62,782
Total investments													$	388,019	$	517	$	(232	)	$	(1,227	)	$	387,077

December 31, 2023
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	$	137,689	$	7	$	(19	)	$	(985	)	$	136,692	$	199,708	$	758	$	(36	)	$	(611	)	$	199,819
Corporate debt securities		94,150		12		(32	)		(1,068	)		93,062		112,055		703		(15	)		(536	)		112,207
Non-U.S. government debt securities		11,784		—		—			(99	)		11,685		4,004		—		—			(8	)		3,996
Total short-term investments		243,623		19		(51	)		(2,152	)		241,439		315,767		1,461		(51	)		(1,155	)		316,022
Long-term investments:
Available-for-sale securities:
U.S. government and agency debt securities		67,979		—		(159	)		(738	)		67,082		19,392		—		(27	)		(315	)		19,050
Corporate debt securities		38,179		—		(44	)		(606	)		37,529		19,306		—		—			(289	)		19,017
		106,158		—		(203	)		(1,344	)		104,611		38,698		—		(27	)		(604	)		38,067
Held-to-maturity securities:
Certificates of deposit		1,820		—		—			—			1,820		1,820		—		—			—			1,820
Total long-term investments		107,978		—		(203	)		(1,344	)		106,431		40,518		—		(27	)		(604	)		39,887
Total investments	$	351,601	$	19	$	(254	)	$	(3,496	)	$	347,870	$	356,285	$	1,461	$	(78	)	$	(1,759	)	$	355,909

December 31, 2022
Short-term investments:
Available-for-sale securities:
Corporate debt securities	$	141,418	$	—	$	(424	)	$	(2,054	)	$	138,940
U.S. government and agency debt securities		143,710		16		(266	)		(1,289	)		142,171
Non-U.S. government debt securities		35,455		—		(28	)		(546	)		34,881
Total short-term investments		320,583		16		(718	)		(3,889	)		315,992
Long-term investments:
Available-for-sale securities:
Corporate debt securities		68,229		—		(1,550	)		(676	)		66,003
U.S. government and agency debt securities		62,220		—		(917	)		(1,424	)		59,879
Non-U.S. government debt securities		4,099		—		—			(191	)		3,908
		134,548		—		(2,467	)		(2,291	)		129,790
Held-to-maturity securities:
Certificates of deposit		1,820		—		—			—			1,820
Total long-term investments		136,368		—		(2,467	)		(2,291	)		131,610
Total investments	$	456,951	$	16	$	(3,185	)	$	(6,180	)	$	447,602

At ~~September 30, 2023,~~March 31, 2024, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. Investments with unrealized losses consisted ~~primarily~~ of corporate debt securities and debt securities issued and backed by U.S. agencies and the U.S. government. At ~~September 30, 2023,~~March 31, 2024, ~~179~~114 of the Company’s ~~219~~248 investment securities were in an unrealized loss position and had an aggregate estimated fair value of $~~280.3~~220.2 million. ~~Approximately~~ 37~~% and~~ 59~~% of the~~The Company’s ~~investment securities at September 30, 2023 were in~~ corporate debt securities ~~with~~investments have a minimum rating of A2 (Moody’s)/A (Standard and Poor’s)~~, and debt securities issued by the U.S. government or its agencies, respectively.~~. The primary reason for the unrealized losses in the Company’s investment portfolio is that its investments are fixed-rate securities acquired in a rising interest rate environment. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company has the intent and ability to hold these investments until recovery, which may be at maturity.

1415

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:


	Nine Months Ended September 30,				Three Months Ended March 31,
(In thousands)	2023		2022		2024		2023
Proceeds from the sales and maturities of investments	$	291,944	$	190,994	$	82,488	$	103,608
Realized gains	$	—	$	—	$	—	$	—
Realized losses	$	—	$	529	$	—	$	—

The Company’s available-for-sale and held-to-maturity securities at ~~September 30, 2023~~March 31, 2024 had contractual maturities in the following periods:


	Available-for-sale				Held-to-maturity				Available-for-sale				Held-to-maturity
	Amortized		Estimated		Amortized		Estimated		Amortized		Estimated		Amortized		Estimated
(In thousands)	Cost		Fair Value		Cost		Fair Value		Cost		Fair Value		Cost		Fair Value
Within 1 year	$	214,322	$	212,122	$	1,820	$	1,820	$	223,529	$	222,712	$	1,820	$	1,820
After 1 year through 5 years		135,459		133,928		—		—		162,670		162,545		—		—
Total	$	349,781	$	346,050	$	1,820	$	1,820	$	386,199	$	385,257	$	1,820	$	1,820

5.6. FAIR VALUE

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques that the Company utilized to determine such fair value:


	September 30,								March 31,
(In thousands)	2023		Level 1		Level 2		Level 3		2024		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	37,132	$	37,132	$	—	$	—
U.S. government and agency debt securities		203,774		166,427		37,347		—	$	243,822	$	210,249	$	33,573	$	—
Corporate debt securities		130,591		—		130,591		—		141,435		—		141,435		—
Non-U.S. government debt securities		11,685		—		11,685		—
Total	$	383,182	$	203,559	$	179,623	$	—	$	385,257	$	210,249	$	175,008	$	—


	December 31,								December 31,
	2022		Level 1		Level 2		Level 3		2023		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	19,857	$	19,857	$	—	$	—	$	34,316	$	34,316	$	—	$	—
U.S. government and agency debt securities		202,050		168,639		33,411		—		218,869		181,041		37,828		—
Corporate debt securities		204,943		—		204,943		—		131,224		—		131,224		—
Non-U.S. government debt securities		38,789		—		38,789		—		3,996		—		3,996		—
Total	$	465,639	$	188,496	$	277,143	$	—	$	388,405	$	215,357	$	173,048	$	—

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

There were no transfers of any securities between levels during the ~~nine~~three months ended ~~September 30, 2023.~~March 31, 2024. At ~~September 30, 2023,~~March 31, 2024, the Company had no investments with fair values that were determined using Level 3 inputs.

The Company’s investments ~~in U.S. government and agency debt securities, non-U.S. government agency debt securities and corporate debt securities~~ classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

~~ALKERMES PLC AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)~~

In April 2015, the Company sold its Gainesville, GA manufacturing facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to intravenous/intramuscular (“IV/IM”) and parenteral forms of Meloxicam to Recro Pharma, Inc. (“Recro”) and Recro Gainesville LLC (such transaction the “Gainesville Transaction”). The Gainesville Transaction included in the purchase price contingent consideration, including milestone payments and royalties on net sales of the IV/IM and parenteral forms of Meloxicam and other products covered under the relevant agreements (such products, the “Meloxicam Products”). In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. (“Baudax”), a publicly-traded pharmaceutical company. As part of this transaction, Recro’s obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

~~In March 2022, Baudax reduced its workforce by approximately~~ 80~~%, which was designed to reduce its operational expenses and conserve its cash resources. As a result of these events and the fact that, at September 30, 2022, Baudax had only paid $1.2~~ ~~million of the $6.4~~ million that was due to the Company in March 2022, the Company determined that it was unlikely to collect any further proceeds under this arrangement and reduced the fair value of the contingent consideration to zero. Accordingly, the Company recorded a $~~3.6~~ ~~million and $21.8~~ million charge within “Change in the fair value of contingent consideration” in the accompanying condensed consolidated statements of operations and comprehensive income (loss) in the three and nine months ended September 30, 2022, respectively. In addition, during the three months ended September 30, 2022, the Company determined that certain construction in progress related to the manufacturing of the approved Meloxicam Product had no future value. See Note 7, ~~Property, Plant and Equipment~~, within the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for details related to such construction in progress. In December 2022, Baudax announced that it would discontinue sales of ANJESO, the first approved Meloxicam Product, and the U.S. Food and Drug Administration (“FDA”) acknowledged the discontinuation of sales of ANJESO via listing in the Orange Book.

In March 2023, the Company and Baudax entered into an agreement pursuant to which Baudax transferred to the Company the rights to certain patents, trademarks, equipment, data and other rights related to ANJESO and agreed to the termination of all prior agreements between the parties and any and all financial and other obligations thereunder.

The carrying amounts reflected in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses, sales discounts, allowances and reserves approximate fair value due to their short-term nature.

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

The estimated fair value of the Company’s long-term debt under its amended and restated credit agreement (such debt, the “2026 Term Loans”), which was based on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $~~281.9~~283.7 million and $~~278.9~~291.0 million at ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, respectively.

6.7. INVENTORY

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Inventory consisted of the following:


	September 30,		December 31,		March 31,		December 31,
(In thousands)	2023		2022		2024		2023
Raw materials	$	68,315	$	61,064	$	76,563	$	71,416
Work in process		73,457		76,228		72,517		68,843
Finished goods(1)		50,414		44,126		49,289		46,147
Total inventory	$	192,186	$	181,418	$	198,369	$	186,406

(1)

At ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, the Company had $~~33.7~~34.2 million and $~~30.9~~33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

~~ALKERMES PLC AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)~~

7.8. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

September 30,

December 31,

(In thousands)

2023

2022

Land

$
6,570

$
6,560

Building and improvements

195,766

195,144

Furniture, fixtures and equipment

436,392

418,448

Leasehold improvements

58,051

54,152

Construction in progress

93,434

84,715

Subtotal

790,213

759,019

Less: accumulated depreciation

(462,696
)

(433,658
)
Total property, plant and equipment, net

$
327,517

$
325,361


	March 31,			December 31,
(In thousands)	2024 (1)			2023 (1)
Land	$	957		$	957
Building and improvements		133,126			132,735
Furniture, fixtures and equipment		243,376			237,728
Leasehold improvements		39,927			39,893
Construction in progress		45,679			45,791
Subtotal		463,065			457,104
Less: accumulated depreciation		(238,475	)		(230,161	)
Total property, plant and equipment, net	$	224,590		$	226,943

As(1)

In connection with the sale of ~~September 30, 2022,~~ the ~~Company determined that~~Athlone Facility, $~~8.7~~94.7 million and $92.2 million of ~~its construction in progress that related to~~ the ~~manufacturing of the approved Meloxicam Product had no future value. In addition, the Company had previously received $6.4~~ ~~million from Baudax related to such~~Company’s property, plant and equipment ~~which it had recorded~~has been classified as ~~contract liabilities within “Other long-term liabilities”~~“Assets held for sale” in the accompanying condensed consolidated balance ~~sheets. These amounts were recognized through “other income (expense), net”~~sheets at March 31, 2024 and December 31, 2023, respectively, and are not included in ~~the accompanying condensed consolidated statements of operations and comprehensive income (loss).~~these amounts.

~~Based on~~In connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, Business Combinations and determined that the Athlone Facility constitutes a business and, accordingly, $2.0 million of the Company’s ~~most recent analysis, amortization of intangible assets included~~goodwill was allocated to the Athlone Facility and is classified as “Assets held for sale” in the accompanying condensed consolidated balance ~~sheet at September 30, 2023 is expected to be approximately $35.0~~ ~~million~~sheets as of March 31, 2024 and $~~1.0~~ ~~million in the years ending~~ December 31, 2023 and ~~2024, respectively. Although~~is not included in the Company believes that such analysis, and the available information and assumptions underlying such analysis, are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future revenues, there is potential for the Company’s actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.amounts above.

At ~~September 30, 2023,~~March 31, 2024, the weighted average incremental borrowing rate and the weighted average remaining lease term for all operating leases held by the Company were ~~5.3~~4.3% and ~~8.1~~8.3 years, respectively. Cash paid for lease liabilities was $~~4.1~~ ~~million and $12.6~~2.5 million during the three ~~and nine~~ months ended ~~September 30, 2023, respectively,~~March 31, 2024, as compared to $~~4.5~~ ~~million and $13.4~~2.8 million during the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2023. The Company recorded operating lease expense from continuing operations of $~~4.2~~ ~~million and $12.7~~1.8 million during the three ~~and nine~~ months ended ~~September 30, 2023, respectively,~~March 31, 2024, as compared to $~~4.1~~ ~~million and $12.5~~2.8 million during the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2023.

On November 13, 2023, in connection with the Separation, Alkermes US and Mural US entered into an assignment and assumption of lease agreement (the “Assignment”), pursuant to which Alkermes US assigned to Mural US an operating lease for approximately 180,000 square feet of corporate office space, administrative areas and laboratories located at 852 Winter Street in Waltham, Massachusetts (the “852 Winter Street Lease”). Under the terms of the Assignment, Mural US assumed all of Alkermes US’ obligations under the 852 Winter Street Lease. In accordance with FASB ASC 842, Leases, as the Company can no longer access or direct the use of the asset following the Assignment, the 852 Winter Street Lease no longer meets the definition of a lease for the Company. On November 15, 2023, the effective date of the Assignment, the Company reduced its right-of-use asset and lease liability by $14.5 million and $15.4 million, respectively, in the accompanying condensed consolidated balance sheets.

~~11. LONG-TERM DEBT~~

~~Long-term debt consisted of the following:~~

September 30,

December 31,

(In thousands)

2023

2022

2026 Term Loans, due March 12, 2026

$
291,366

$
293,270

Less: current portion

(3,000
)

(3,000
)
Long-term debt

$
288,366

$
290,270

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

12. LONG-TERM DEBT

Long-term debt consisted of the following:


	March 31,			December 31,
(In thousands)	2024			2023
2026 Term Loans, due March 12, 2026	$	290,095		$	290,730
Less: current portion		(3,000	)		(3,000	)
Long-term debt	$	287,095		$	287,730

The 2026 Term Loans mature on March 12, 2026. In June 2023, the Company amended the 2026 Terms Loans to transition the interest rate available for borrowings thereunder from a London Interbank Offered Rate (“LIBOR”)-based interest rate to an interest rate based on the Secured Overnight Financing Rate (“SOFR”) and to make other conforming and mechanical changes.The 2026 Term Loans bear interest at ~~SOFR~~the Secured Overnight Financing Rate plus a credit spread adjustment applicable to the interest period and an applicable margin of 2.50% with a floor of 0.5%.

The 2026 Term Loans have an incremental facility capacity in the amount of $175.0 million plus additional amounts, provided that the Company meets certain conditions, including a specified leverage ratio. The Company was in compliance with its debt covenants at ~~September 30, 2023.~~March 31, 2024.

~~12.~~13. SHARE-BASED COMPENSATION

The following table presents share-based compensation expense from continuing and discontinued operations included in the accompanying condensed consolidated statements of operations and comprehensive income (loss):


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 30,				September 30,				March 31,
(In thousands)	2023		2022		2023		2022		2024		2023
Cost of goods manufactured and sold	$	2,939	$	2,623	$	8,542	$	7,406	$	2,906	$	2,682
Research and development		7,208		6,858		21,621		19,688		10,278		5,764
Selling, general and administrative		13,768		16,570		44,899		40,677		19,571		12,577
Share-based compensation expense from continuing operations										32,755		21,023
Cost of goods manufactured and sold										—		—
Research and development										—		1,143
Selling, general and administrative										—		477
Share-based compensation expense from discontinued operations										—		1,620
Total share-based compensation expense	$	23,915	$	26,051	$	75,062	$	67,771	$	32,755	$	22,643

At ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, $~~3.2~~3.3 million and $~~3.3~~3.2 million, respectively, of share-based compensation expense was capitalized and recorded as “Inventory” in the accompanying condensed consolidated balance sheets.

~~On June 29, 2023,~~In February 2021, the compensation committee of the Company’s ~~shareholders~~board of directors approved ~~an amended version~~the grant of performance-based restricted stock units to employees of the ~~Alkermes plc 2018~~ Company at the Senior Vice President level and above, in each case subject to vesting based on the achievement of certain financial, commercial and R&D performance criteria to be assessed over a performance period of three years from the date of the grant, and subject, at the end of such three-year performance period, to upward or downward adjustment based on a market condition tied to relative share price performance over the three-year performance period. On February 8, 2024, the compensation committee of the Company’s board of directors determined that the Company partially achieved the financial performance criteria. This was considered a modification in accordance with FASB ASC 718, Compensation—Stock ~~Option~~Compensation (“Topic 718”) and ~~Incentive Plan~~resulted in a modification charge of approximately $6.8 million. On February 8, 2024, the compensation committee of the Company’s board of directors also determined that ~~served~~the Company achieved the pipeline performance criteria for these awards, resulting in a $2.6 million incremental share-based compensation expense, as it was deemed such pipeline performance criteria had been met. The share-based compensation expense related to ~~among other things, increase~~these achievements was recognized in the ~~number~~first quarter of ~~ordinary shares authorized for issuance thereunder by~~ 2024.~~6,500,000~~.

~~13.~~19

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

14. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per ordinary share is calculated based upon net income (loss) available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the effect of outstanding ordinary share equivalents such as stock options and restricted stock unit awards.


	Three Months Ended
	March 31,
(In thousands)	2024			2023 (1)
Numerator:
Net income (loss) from continuing operations	$	38,948		$	(12,050	)
Net loss from discontinued operations		(2,120	)		(29,795	)
Net income (loss)	$	36,828		$	(41,845	)
Denominator:
Weighted average number of ordinary shares outstanding		167,984			165,085
Effect of dilutive securities:
Stock options		1,734			—
Restricted stock unit awards		3,263			—
Dilutive ordinary share equivalents		4,997			—
Shares used in calculating diluted earnings (loss) per ordinary share		172,981			165,085

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In thousands)

2023

2022

2023

2022

Numerator:

Net income (loss)

$
47,758

$
(63,974
)

$
242,978

$
(130,013
)
Denominator:

Weighted average number of ordinary shares outstanding

166,607

164,282

165,996

163,541

Effect of dilutive securities:

Stock options

1,682

—

1,643

—

Restricted stock unit awards

3,614

—

3,342

—

Dilutive ordinary share equivalents

5,296

—

4,985

—

Shares used in calculating diluted earnings (loss) per ordinary share

171,903

164,282

170,981

163,541

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The following potential ordinary share equivalents were not included in the net earnings (loss) per ordinary share calculation because the effect would have been anti-dilutive:

~~ALKERMES PLC AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)~~


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 30,				September 30,				March 31,
(In thousands)	2023		2022		2023		2022		2024		2023
Stock options		12,029		13,031		12,422		12,784		11,152		13,007
Restricted stock unit awards		1,317		4,922		2,389		5,459		1,776		6,093
Total		13,346		17,953		14,811		18,243		12,928		19,100

~~14.~~15. INCOME TAXES

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In determining future taxable income, the Company is responsible for assumptions that it utilizes, including the amount of Irish and non-Irish ~~pre‑tax~~pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company uses to manage the underlying business.

The Company recorded an income tax ~~benefit~~provisions of $~~0.4~~8.0 million and $~~3.7~~0.7 million during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023, ~~respectively,~~respectively. The income tax provision during the three months ended March 31, 2024 was primarily attributable to taxes on income earned in Ireland. The income tax provision during the three months ended March 31, 2023 was primarily due to ~~enhanced foreign derived intangible~~U.S. federal and state taxes on income ~~(“FDII”) deductions arising from the capitalization of research and development expenses~~earned in ~~accordance with Section 174 of~~ the U.S. ~~Internal Revenue Code~~and the tax impact of ~~1986, as amended.~~

On a quarterly basis, the Company reassesses the valuation allowance on its deferred tax assets, weighing positive and negative evidence to determine the recoverability of such deferred tax assets. In the fourth quarter of 2022, the Company reassessed the valuation allowance and considered all positive and negative evidence, including its cumulative losses over the years ended December 31, 2022, 2021 and 2020 and concluded that it should maintain the valuation allowance on its Irish net operating losses and other deferred tax assets as of December 31, 2022.employee equity activity.

The Company may release a significant portion of the valuation allowance upon completion of the planned separation of its oncology business; however, the release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Company’s level of profitability, revenue growth, clinical program progression, the successful completion of the planned separation of the oncology business and expectations regarding future profitability. The Company’s Irish deferredeffective tax ~~asset balance subject to the valuation allowance was approximately $245.8~~ ~~million at December 31, 2022.~~

~~15. RESTRUCTURING~~

In ~~July 2023~~, in conjunction with the Company’s ongoing review of operations and the planned separation of its oncology business, the Company implemented a restructuring plan, which included the elimination of approximately 60 ~~positions across the Company (the “Restructuring”). The Company recorded a charge of $6.0~~ ~~million~~rate during the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 was 17.0%, which exceeds the Irish statutory tax rate of 12.5%, primarily due to non-deductible expenses and income that was taxable at rates higher than the Irish statutory tax rate. The income tax provision recorded as ~~a result~~of March 31, 2024 took into account the estimated impact of the Restructuring, which consisted of one-time termination benefits for employee severance, benefits and related costs, all of which are expected to result in cash expenditures, and all of which are expected to be paid within 12 monthsglobal minimum tax rate component, known as Pillar Two, of the ~~Restructuring. During the three~~Organization for Economic Co-operation and ~~nine months ended September 30, 2023, the Company recognized $4.5~~ ~~million and $1.5~~ ~~million~~Development’s two-pillar plan on global tax reform, which became effective in Ireland as of ~~this expense in R&D expense and SG&A expense, respectively, in the accompanying condensed consolidated statements of comprehensive income (loss).~~January 1, 2024 for

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

~~Activity related to the Restructuring during the three months ended September 30, 2023 was as follows:~~

(In thousands)

Balance, December 31, 2022

$
—

Restructuring charge

5,969

Amounts paid during the period:

Severance

(2,098
)
Benefits

(319
)
Outplacement services

(178
)
Balance, September 30, 2023

$
3,374

~~At September 30, 2023 and December 31, 2022, $~~multinational companies with consolidated annual revenue of at least €~~3.4~~750.0 ~~million and~~ no~~ne, respectively, of~~million. The Company does not expect Pillar Two to have a material impact for the ~~restructuring accrual was included within “Accounts payable and accrued expenses” in the accompanying condensed consolidated balance sheets.~~current year.

16. COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company’s best estimates, utilizing all available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company’s operating results. At ~~September 30, 2023,~~March 31, 2024, there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring.

~~Janssen Arbitration Proceedings~~

~~In April 2022, Alkermes Pharma Ireland Limited commenced binding arbitration proceedings to settle, among other things, whether, notwithstanding Janssen Pharmaceutica’s partial termination of~~ ~~two~~ license agreements with the Company, Janssen Pharmaceutica has a continuing obligation to pay royalties on sales in the U.S. of INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA and CABENUVA. On May 31, 2023, the Company received a Final Award from the Tribunal in these arbitration proceedings. The Final Award reiterated the Tribunal’s findings from, and incorporated by reference, the first interim award and second interim award issued by the Tribunal on December 21, 2022 and April 19, 2023, respectively. As a result of the Final Award, in June 2023 the Company received payment for back royalties, including certain late-payment interest, related to 2022 U.S. net sales of INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA and CABENUVA and is entitled to 2023 and future royalty revenues from Janssen Pharmaceutica related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the applicable license agreement expires), INVEGA HAFYERA through May 2030 (when the applicable license agreement expires) and CABENUVA through December 31, 2036. Refer to Note 3, ~~Revenue from Contracts with Customers~~ within the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for additional information regarding royalty revenue recognized following the issuance of the Final Award. The arbitration was conducted pursuant to the Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered Arbitration before a panel of three arbitrators. On June 28, 2023, the Company filed an unopposed petition to confirm the Final Award and enter judgment thereon with the U.S. District Court for the Southern District of New York (the “NY Southern District Court”), and on June 30, 2023, Janssen Pharmaceutica filed a notice of non-opposition to such petition. On August 18, 2023, the NY Southern District Court granted the Company’s motion to confirm the Final Award.

INVEGA SUSTENNA ANDA Litigation

Janssen Pharmaceutica and Janssen Pharmaceuticals, Inc. initiated patent infringement lawsuits in the U.S. District Court for the District of New Jersey (the “NJ District Court”) in January 2018 against Teva Pharmaceuticals USA, Inc. (“Teva”) and Teva Pharmaceuticals Industries, Ltd. (“Teva PI”) (such lawsuit, the “Teva Lawsuit”), in August 2019

~~ALKERMES PLC AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)~~

against Mylan Laboratories Limited (“Mylan Labs”) and other Mylan entities (the “Mylan Lawsuit”), in December 2019 against Pharmascience, Inc. (“Pharmascience”), Mallinckrodt plc, and SpecGX LLC (the “Pharmascience Lawsuit”), and in February 2022 against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd (“Accord” and such lawsuit, the “Accord Lawsuit”), and in the U.S. District Court for the District of Delaware (the “DE District Court”) in December 2021 against Tolmar Holding, Inc., Tolmar Pharmaceuticals, Inc., Tolmar Therapeutics, Inc., and Tolmar, Inc. (“Tolmar” and such lawsuit, the “Tolmar Lawsuit”), following the respective filings by each of Teva, Mylan Labs, Pharmascience, Accord and Tolmar of an Abbreviated New Drug Application (“ANDA”) seeking approval from the FDA to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906. In October 2021, the NJ District Court entered a judgment in favor of the Janssen entities in the Teva Lawsuit. In December 2021, the NJ District Court entered a judgment in favor of the Janssen entities in the Mylan Lawsuit, based on the parties’ prior stipulation to be bound by the judgment in the Teva Lawsuit. The Teva entities and Mylan Labs each filed notices of appeal of their respective judgments with the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit Court”), which were consolidated in January 2022 (the “Teva Appeal”). ~~A trial was held in the Tolmar Lawsuit in October 2023.~~ The Pharmascience Lawsuit and the Accord Lawsuit were administratively terminated in July 2022, pending the outcome of the Teva Appeal. The Company is not a party to any of these proceedings. On April 1, 2024, the Federal Circuit Court issued a decision affirming in part and vacating and remanding in part the NJ District Court’s judgment. A trial was held in the Tolmar Lawsuit in October 2023 and on March 13, 2024, the DE District Court issued a decision, following which a notice of appeal and certain post-trial motions were filed in April 2024.

INVEGA TRINZA ANDA Litigation

In September 2020, Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC initiated a patent infringement lawsuit in the NJ District Court against Mylan Labs, Mylan, and Mylan Institutional LLC following the filing by Mylan Labs of an ANDA seeking approval from the FDA to market a generic version of INVEGA TRINZA before the expiration of U.S. Patent No. 10,143,693 (the “’693 Patent”). Requested judicial remedies include recovery of litigation costs and injunctive relief. In May 2023, the NJ District Court issued an opinion in favor of the Janssen entities on the issues of infringement and validity of the ’693 Patent and the Mylan entities filed a notice of appeal of the decision. The Company is not a party to this proceeding.

~~VIVITROL ANDA Litigation~~

In September 2020, Alkermes, Inc. and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the NJ District Court against Teva and Teva PI following the filing by Teva of an ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a generic version of VIVITROL (naltrexone for extended-release injectable suspension) before the expiration of the Company’s U.S. Patent No. 7,919,499.

A bench trial was held in February 2023 and closing arguments were heard in June 2023. On August 29, 2023, Alkermes, Inc. and Alkermes Pharma Ireland Limited entered into a confidential settlement and license agreement (the “Settlement Agreement”) with Teva to resolve the proceedings between the parties. Pursuant to the terms of the Settlement Agreement, the Company has granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to make, have made, use, import, sell and offer for sale Teva’s product made under Teva’s ANDA in the U.S. beginning on January 15, 2027, or earlier under certain circumstances. The Company and the Teva entities have submitted the Settlement Agreement for review to the U.S. Federal Trade Commission and the U.S. Department of Justice. Pursuant to the Settlement Agreement, on August 30, 2023, the Company and Teva filed a joint proposed Stipulated Consent Judgment and Injunction with the NJ District Court requesting that the court dismiss the pending litigation proceedings between the parties. On September 18, 2023, the NJ District Court approved such Stipulated Consent Judgment and Injunction.

VUMERITY ANDA Litigation

OnIn July 6, 2023, Biogen Inc., Biogen Swiss Manufacturing GmbH and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the DE District Court against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (collectively, “Zydus”) following the filing by Zydus of an ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a generic version of VUMERITY (diroximel fumarate) delayed-release capsules for oral use, 231 mg, before expiration of the Company’s U.S. Patent Nos. 8,669,281;

ALKERMES PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)

9,090,558; and 10,080,733. The filing of the lawsuit triggered a stay of FDA approval of the ANDA for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”). ~~On October 11, 2023, Zydus filed an answer~~A bench trial is scheduled to ~~the complaint.~~

~~ALKERMES PLC AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)~~

begin on July 28, 2025.

Government Matters

The Company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL. The Company is cooperating with the investigations.

Product Liability and Other Legal Proceedings

The Company is involved in litigation and other legal proceedings incidental to its normal business activities, including product liability cases alleging that the FDA-approved VIVITROL labeling was inadequate and caused the users of the product to suffer from opioid overdose and death. The Company intends to vigorously defend itself in these matters.

In addition, in January 2023, Acorda filed a petition with the NYU.S. District Court for the Southern District ~~Court~~of New York (the “NY Southern District Court”) asking the court to confirm in part and modify in part the final arbitral award rendered by an arbitration panel in October 2022 and, as part of the requested modification, seeking an additional approximately $66.0 million in damages. OnIn August 4, 2023, the NY Southern District Court confirmed the final arbitral award ~~but~~and declined to modify the final award to increase the damages awarded thereunder. OnIn September 1, 2023, Acorda filed a notice of appeal of the NY Southern District Court decision to the ~~U.S.~~Federal Circuit Court, ~~of Appeals for the Federal Circuit. On September 22, 2023,~~and the Company filed a motion to transfer the appeal to the U.S. Court of Appeals for the Second ~~Circuit and on~~Circuit. In October ~~10,~~ 2023, Acorda filed an opposition to such motion. On January 18, 2024, the Federal Circuit Court denied without prejudice the Company’s motion to transfer the appeal and instructed the parties to brief the jurisdictional question as part of the merits appeal.

While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing proceedings would have a material adverse effect on the Company’s business or financial condition.

23Guarantees

In connection with the Separation, the Company entered into the Assignment related to the 852 Winter Street Lease, which is described in more detail in Note 10, Leases in the “Notes to Consolidated Financial Statements” in the Annual Report. Although the Assignment transferred all of the rights, title and interest in, to and under the 852 Winter Street Lease to Mural US as of November 15, 2023, the Company ratified and reaffirmed for the remainder of the lease term its guarantor obligations under that certain Guaranty dated as of May 16, 2014 related to the 852 Winter Street Lease. This lease expires in 2026 and includes a tenant option to extend the term for an additional five-year period. Upon completion of the Separation, the Assignment was accounted for as a termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 852 Winter Street Lease. At March 31, 2024, the fair value of the guarantee was not material to the Company.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the accompanying condensed consolidated financial statements and related notes beginning on page 5 in this Form 10-Q, and “Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the audited financial statements and notes thereto accompanying our Annual Report.

Executive Summary

Net income from continuing operations was ~~$47.8 million and $243.0~~$38.9 million or $0.29 and $1.46 per ordinary share—basic and $0.28 and $1.42 per ordinary share—diluted, for the three and nine months ended September 30, 2023, respectively, as compared to net loss of $64.0 million and $130.0 million or $0.39 and $0.79$0.23 per ordinary share—basic and diluted, for the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2024, compared to net loss from continuing operations of $12.1 million or $0.07 per ordinary share—basic and diluted, for the three months ended March 31, 2023.

The net income from continuing operations during the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, as compared to the net loss from continuing operations during the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, was primarily due to ~~increases~~an increase of ~~$96.2~~$44.0 million ~~and $364.5 million, respectively,~~ in manufacturing and royalty revenues, ~~primarily from the Long-acting INVEGA products following the successful outcome~~an increase of ~~the arbitration proceedings in respect of such products, and increases of $32.4~~$18.8 million ~~and $116.6 million, respectively,~~ in product sales, net and a decrease of $7.7 million in amortization of acquired intangible assets, partially offset by ~~increases~~an increase of ~~$16.7~~$11.9 million ~~and $101.0 million, respectively,~~ in selling, general and administrative expense, and ~~increases~~an increase of ~~$10.9~~$6.4 million ~~and $18.8 million, respectively,~~ in ~~cost of goods manufactured and sold.~~R&D expense.

These items are discussed in greater detail later in the “Results of Operations” section in this “Part I, Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q.

~~Planned Separation of Oncology~~ Business Update

~~In November 2022,~~On May 1, 2024, we completed the previously announced our intent, as approved by our board of directors, to explore the separation of our oncology business. Following a review of strategic alternatives for the oncology business, we are planning a separationsale of the oncology business into an independent, publicly-traded company, Mural Oncology. Following the planned separation, we would focus on driving growth of our proprietary commercial products: LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders.Athlone Facility to Novo. We also ~~expect~~entered into subcontracting arrangements with Novo to ~~retain~~continue certain development and manufacturing ~~and royalty revenues, including those related to our licensed products and third-party products using our proprietary technologies under license. Mural Oncology would focus on~~activities currently performed at the ~~discovery and development~~Athlone Facility for a period of ~~cancer therapies, including~~time after the continued development of nemvaleukin alfa and our portfolio of novel, preclinical engineered cytokines. The separation, if consummated, is expected to be completed in November 2023 and is subject to customary closing conditions, including final approval by our board of directors and receipt of a private letter ruling from the IRS and/or a tax opinion from our tax advisor. Subsequent to the planned separation, the historical results of the ~~oncology business will be reflected as discontinued operations in our consolidated financial statements.~~

~~COVID-19 Impact~~

A number of the marketed products from which we derive revenue, including manufacturing and royalty revenue, are injectable medications administered by healthcare professionals, which have been adversely impacted to varying degrees as a result of COVID-19 related impacts. We are continuing to monitor any potential COVID-19 related impacts on our employees, business, financial condition and results of operations. For information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see “Item 1A—Risk Factors” in our Annual Report and specifically the section entitled “Our business, financial condition and results of operations have been, andtransaction; these activities may continue ~~to be, adversely affected by~~through the ~~ongoing COVID-19 pandemic or other similar outbreaks~~end of ~~contagious diseases.”~~2025.

Products

Marketed Products

The key marketed products discussed below have generated, or are expected to generate, significant revenues for us. See the descriptions of the marketed products below and “Part I, Item 1A—Risk Factors” in our Annual Report for important factors that could adversely affect our marketed products. See the “Patents and Proprietary Rights” section in

~~“Part~~ “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for these marketed products.

~~Proprietary Products~~23

The following provides summary information regarding our proprietary products that we commercialize:

Proprietary Products


Product	Indication(s)	Territory

	Initiation or re-initiation of ARISTADA for the treatment of Schizophrenia	U.S.
	Schizophrenia	U.S.


	Schizophrenia; Bipolar I disorder	U.S.


	Alcohol dependence; Opioid dependence	U.S.

2524

~~Key Third-Party Products Using Our Proprietary Technologies~~

The following provides summary information regarding certain key third-party products using our proprietary technologies under license and our key licensed product, that are commercialized by our licensees:

Key Third-Party Products Using Our Proprietary Technologies


Product	Indication(s)	Licensee	Licensed Territory

~~RISPERDAL CONSTA~~	~~Schizophrenia; Bipolar I~~ ~~disorder~~	~~Janssen~~ ~~Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (“Janssen International”)~~	~~Worldwide~~

INVEGA SUSTENNA / XEPLION	INVEGA SUSTENNA: Schizophrenia; Schizoaffective disorder XEPLION: Schizophrenia	Janssen Pharmaceutica (together with Janssen Pharmaceuticals, Inc., Janssen International and their affiliates “Janssen”)	Worldwide
INVEGA TRINZA / TREVICTA	Schizophrenia	Janssen	Worldwide
INVEGA HAFYERA / BYANNLI	Schizophrenia	Janssen	Worldwide

Our Key Licensed Product

~~The following provides summary information regarding our key licensed product that is commercialized by our licensees:~~

~~The following sections provide more detailed information regarding our proprietary products, licensed products and products using our proprietary technology.~~

Proprietary Products

We have developed and now commercialize products designed to help address the unmet needs of people living with opioid dependence, alcohol dependence, schizophrenia and bipolar I disorder. See the “Patents and Proprietary Rights” section in “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for our proprietary products.

ARISTADA

ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA utilizes our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is available in four dose strengths with once-monthly dosing options (441 mg, 662 mg and 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg). ARISTADA is packaged in a ready-to-use, pre-filled syringe product format. We exclusively manufacture and commercialize ARISTADA in the U.S.

In April 2024, U.S. Patent No. 11,969,469 relating to ARISTADA was granted. This patent has claims to pharmaceutical compositions that confer long-term stability of the ARISTADA formulation and expires in 2033.

ARISTADA INITIO

ARISTADA INITIO (aripiprazole lauroxil) leverages our proprietary LinkeRx and NanoCrystal technologies and provides an extended-release formulation of aripiprazole lauroxil in a smaller particle size compared to ARISTADA, thereby enabling faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. ARISTADA INITIO, combined with a single 30 mg dose of oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. The first ARISTADA dose may be administered on the same day as the ARISTADA INITIO regimen or up to 10 days thereafter. We exclusively manufacture and commercialize ARISTADA INITIO in the U.S.

LYBALVI

LYBALVI (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, in a single bilayer tablet. LYBALVI ~~was launched commercially in October 2021 and~~ is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine. We exclusively manufacture and commercialize LYBALVI in the U.S.

In July 2023, U.S. Patent No. 11,707,466 relating to LYBALVI was granted. The patent has claims to formulations that cover LYBALVI and expires in 2041. In October 2023, U.S. Patent No. 11,793,805 relating to LYBALVI was granted. The patent has claims to methods of treatment that cover LYBALVI and expires in 2031.

VIVITROL

VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S. for the treatment of alcohol dependence in patients able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We exclusively manufacture and commercialize VIVITROL in the U.S.

~~For a discussion of legal proceedings related to VIVITROL, see Note 16,~~ ~~Commitments and Contingent Liabilities~~ ~~in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q.~~

~~Licensed Products and~~ Products Using Our Proprietary Technologies and Licensed Product

We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable them to develop, commercialize and/or manufacture products. See the “Proprietary Technology Platforms” and “Patents and Proprietary Rights” sections in “Part I, Item 1—Business” in our Annual Report for information with respect to our proprietary technologies and the IP protection for these products. We receive royalties and/or manufacturing and other revenues from the commercialization of these products under our collaborative arrangements with these third parties. Such arrangements, among others, include the following:

~~Key~~ Products Using Our Proprietary Technologies

INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI

The ~~Long-acting~~long-acting INVEGA products are long-acting atypical antipsychotics owned and commercialized worldwide by Janssen. We believe that these products incorporate our technologies.

INVEGA SUSTENNA is approved in the U.S. for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union (“EU”) and other countries outside of the U.S. for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured by Janssen.

INVEGA TRINZA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months. TREVICTA is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION. INVEGA TRINZA/TREVICTA is manufactured by Janssen.

INVEGA HAFYERA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months or INVEGA TRINZA for at least three months. BYANNLI is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION or TREVICTA. INVEGA HAFYERA/BYANNLI is manufactured by Janssen.

For a discussion of legal proceedings related to certain of the patents covering INVEGA SUSTENNA and INVEGA TRINZA, see Note 16, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q and for information about risks relating to such legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically the section entitled “We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

~~RISPERDAL CONSTA~~26

RISPERDAL CONSTA (risperidone long-acting injection) is a long-acting atypical antipsychotic owned and commercialized worldwide by Janssen that incorporates our proprietary technologies. RISPERDAL CONSTA is approved in the U.S. for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is approved in numerous countries outside of the U.S. for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one intramuscular injection every two weeks. RISPERDAL CONSTA microspheres are exclusively manufactured by us.

Licensed Product

VUMERITY

VUMERITY (diroximel fumarate) is a novel, oral fumarate with a distinct chemical structure that is approved in the U.S., the EU and several other countries for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY. For more information about the license and collaboration agreement with Biogen, see the “Collaborative Arrangements—Biogen” section in “Part I, Item 1—Business” in our Annual Report. For a discussion of legal proceedings related to certain of the patents covering VUMERITY, see Note 16, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q and for information about risks relating to such legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report and specifically the section entitled “We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

Key Development ~~Programs~~Program

Our R&D is focused on the development of innovative medicines in the ~~fields~~field of neuroscience ~~and oncology~~ that are designed to address unmet patient needs. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. The discussion below highlights our current key development ~~programs.~~program. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in “Part I, Item 1A—Risk Factors” in our Annual ~~Report and “Part II, Item 1A—Risk Factors” in this Form 10-Q.~~Report. See the “Patents and Proprietary Rights” section in “Part I, Item 1—Business” in our Annual Report for information with respect to the IP protection for our key development ~~programs.~~

~~Nemvaleukin alfa~~

Nemvaleukin alfa (“nemvaleukin”) is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (“IL-2”) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

ARTISTRY is our clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous (“IV”) and subcutaneous (“SC”) dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. ARTISTRY-6 is an ongoing phase 2 study evaluating the anti-tumor activity, safety and tolerability of IV nemvaleukin monotherapy in patients with mucosal melanoma and SC nemvaleukin monotherapy in patients with advanced cutaneous melanoma. ARTISTRY-7 is an ongoing phase 3 study evaluating the efficacy, safety and tolerability of IV nemvaleukin as monotherapy and in combination with pembrolizumab compared to investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer.

In March 2021 and August 2021, we announced that the FDA granted Orphan Drug designation and Fast Track designation, respectively, to nemvaleukin for the treatment of mucosal melanoma. In October 2021, we announced that the FDA granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer. In January 2023, we announced that the Medicines and Healthcare products Regulatory Agency (“MHRA”), the regulatory body of the United Kingdom (“UK”), had granted an Innovation Passport designation for nemvaleukin for the treatment of mucosal melanoma under the UK’s Innovative Licensing and Access Pathway (“ILAP”).program.

ALKS 2680

ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (“OX2R”) agonist in development ~~for the~~as a once-daily treatment offor narcolepsy. Orexin neuropeptides are important regulators of the sleep/wake cycle through OX2R activation, and loss of orexinergic neurons in the brain is associated with excessive daytime sleepiness and cataplexy in narcolepsy. ALKS 2680 was designed to address the underlying pathology of narcolepsy with the goal of improving duration of wakefulness and providing cataplexy control. ~~Once-daily oral administration of~~ ALKS 2680 ~~is currently being~~was evaluated in a phase 1 study in healthy volunteers and ~~people living~~patients with narcolepsy type 1, narcolepsy type 2 and idiopathic ~~hypersomnia.~~hypersomnia and is currently being evaluated in a phase 2 study in patients with narcolepsy type 1. We expect to initiate a planned phase 2 study in patients with narcolepsy type 2 in the second half of 2024.

2927

Results of Operations

As a result of the Separation, the historical results of our oncology business have been reflected as discontinued operations in our consolidated financial statements through the Separation Date. Prior period results of operations and balance sheet information have been recast to reflect this presentation.

Product Sales, Net

Our product sales, net, consist of sales of VIVITROL, ARISTADA and ARISTADA INITIO, and ~~following its commercial launch in the U.S. in October 2021,~~ LYBALVI, primarily to wholesalers, specialty distributors and pharmacies. The following table presents the adjustments deducted from product sales, gross to arrive at product sales, net, for sales of VIVITROL, ARISTADA and ARISTADA INITIO, and LYBALVI during the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:


	Three Months Ended														Nine Months Ended														Three Months Ended
	September 30,														September 30,														March 31,
(In millions, except for % of Sales)	2023			% of Sales				2022			% of Sales				2023			% of Sales				2022			% of Sales				2024			% of Sales				2023			% of Sales
Product sales, gross	$	469.3			100.0		%	$	401.0			100.0		%	$	1,373.0			100.0		%	$	1,130.2			100.0		%	$	467.3			100.0		%	$	433.9			100.0		%
Adjustments to product sales, gross:
Medicaid rebates		(107.2	)		(22.8	)	%		(88.9	)		(22.2	)	%		(317.5	)		(23.1	)	%		(254.1	)		(22.5	)	%		(105.0	)		(22.5	)	%		(97.9	)		(22.6	)	%
Chargebacks		(48.9	)		(10.4	)	%		(43.0	)		(10.7	)	%		(141.4	)		(10.3	)	%		(118.3	)		(10.5	)	%		(50.5	)		(10.8	)	%		(45.4	)		(10.5	)	%
Product discounts		(32.7	)		(7.0	)	%		(32.6	)		(8.1	)	%		(101.8	)		(7.4	)	%		(90.3	)		(8.0	)	%		(34.3	)		(7.3	)	%		(34.5	)		(8.0	)	%
Medicare Part D		(18.7	)		(4.0	)	%		(17.1	)		(4.3	)	%		(55.8	)		(4.1	)	%		(49.6	)		(4.4	)	%		(17.4	)		(3.7	)	%		(18.9	)		(4.4	)	%
Other		(30.0	)		(6.4	)	%		(20.1	)		(5.0	)	%		(78.5	)		(5.7	)	%		(56.5	)		(4.9	)	%		(26.6	)		(5.7	)	%		(22.5	)		(5.1	)	%
Total adjustments		(237.5	)		(50.6	)	%		(201.7	)		(50.3	)	%		(695.0	)		(50.6	)	%		(568.8	)		(50.3	)	%		(233.8	)		(50.0	)	%		(219.2	)		(50.5	)	%
Product sales, net	$	231.8			49.4		%	$	199.3			49.7		%	$	678.0			49.4		%	$	561.4			49.7		%	$	233.5			50.0		%	$	214.7			49.5		%

VIVITROL product sales, gross, increased by 2% during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, primarily due to a 3.2% increase in the selling price that went into effect in January 2024, partially offset by a 1% decrease in the number of units sold. ARISTADA and ARISTADA INITIO product sales, gross, were relatively flat during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, due to a 3.0% increase in the selling price that went into effect in January 2024, partially offset by a 3% decrease in the number of units sold. LYBALVI product sales, gross, increased by 56% during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, primarily due to a 50% increase in the number of units sold and 3% and 3.8% increases in the selling price that went into effect in July 2023 and January 2024, respectively.

The following table compares product sales, net earned during the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In millions)
2023

2022

Change

2023

2022

Change

VIVITROL
$
99.3

$
96.5

$
2.8

$
298.0

$
277.5

$
20.5

ARISTADA and ARISTADA INITIO

81.8

75.7

6.1

244.3

222.8

21.5

LYBALVI

50.7

27.1

23.6

135.7

61.1

74.6

Product sales, net
$
231.8

$
199.3

$
32.5

$
678.0

$
561.4

$
116.6

VIVITROL product sales, gross, increased by 9% and 14% during the three and nine months ended September 30, 2023, respectively, as compared to the three and nine months ended September 30, 2022, primarily due to increases of 3% and 6%, respectively, in the number of units sold and a 6% increase in the selling price that went into effect in January 2023. ARISTADA and ARISTADA INITIO product sales, gross, increased by 12% and 13% during the three and nine months ended September 30, 2023, respectively, as compared to the three and nine months ended September 30, 2022, primarily due to increases of 9% and 10%, respectively, in the number of units sold and a 3% increase in the selling price that went into effect in January 2023. LYBALVI product sales, gross, increased by 85% and 120% during the three and nine months ended September 30, 2023, respectively, as compared to the three and nine months ended September 30, 2022, primarily due to increases of 76% and 114%, respectively, in the number of units sold and increases in the selling price of 6% and 3% that went into effect in November 2022 and July 2023, respectively.


	Three Months Ended
	March 31,
(In millions)	2024		2023		Change
VIVITROL	$	97.7	$	96.7	$	1.0
ARISTADA and ARISTADA INITIO		78.9		80.1		(1.2	)
LYBALVI		57.0		37.9		19.1
Product sales, net	$	233.5	$	214.7	$	18.9

Manufacturing and Royalty Revenues

The following table compares manufacturing and royalty revenues earned during the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:


	Three Months Ended							Nine Months Ended							Three Months Ended
	September 30,							September 30,							March 31,
(In millions)	2023		2022			Change		2023		2022		Change			2024		2023		Change
Manufacturing and royalty revenues:
Long-acting INVEGA products	$	76.1	$	26.7		$	49.4	$	410.9	$	90.4	$	320.5		$	62.7	$	13.6	$	49.1
VUMERITY		34.5		26.2			8.3		95.7		83.0		12.7			31.3		28.9		2.4
RISPERDAL CONSTA		14.9		10.2			4.7		31.0		38.0		(7.0	)
Other		23.6		(10.2	)		33.8		70.3		32.0		38.3			22.8		30.4		(7.6	)
Manufacturing and royalty revenues	$	149.1	$	52.9		$	96.2	$	607.9	$	243.4	$	364.5		$	116.8	$	72.9	$	43.9

3028

Our agreements with Janssen related to the ~~Long-acting~~long-acting INVEGA products provide for tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% on calendar year net sales up to $250 million; 5.5% on calendar year net sales of between $250 million and $500 million; and 7.5% on calendar year net sales exceeding $500 million. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from the first commercial sale of a product in each individual country, subject to expiry of the agreement. For more information about the license agreement with Janssen in respect of the ~~Long-acting~~long-acting INVEGA products, see the “Collaborative Arrangements—Janssen” section in “Part I, Item 1—Business” in our Annual Report.

In November 2021, we received notice from Janssen of partial termination of our license agreement ~~with Janssen~~ under which we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our ~~small particle pharmaceutical compound technology, known as~~ NanoCrystal technology, which was used to develop the ~~Long-acting~~long-acting INVEGA products. The partial termination became effective in February 2022, at which time Janssen ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. Accordingly, we ceased recognizing royalty revenue related to sales of these products in February 2022. In April 2022, we commenced binding arbitration proceedings related to, among other things, Janssen’s partial termination of this license agreement and Janssen’s royalty and other obligations under the agreement. In May 2023, the Tribunal issued the Final Award, which concluded the arbitration proceedings. The Final Award provided that we were due back royalties ~~of $195.4 million, inclusive of $8.1 million in~~and late-payment interest related to 2022 U.S. net sales of the ~~Long-acting~~long-acting INVEGA products, which we received from Janssen in the second quarter of 2023, and are entitled to 2023 and future royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

Following issuance of the Final Award, we recognized royalty revenues related to the back royalties ~~noted above~~ and resumed recognizing royalty revenue related to U.S. sales of the ~~Long-acting~~long-acting INVEGA products. Royalty revenues related to the long-acting INVEGA products increased by $49.1 million during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, primarily due to the result of the arbitration proceedings in the second quarter of 2023 and the resumption of recognizing royalty revenue on U.S. net sales of the long-acting INVEGA products. During the three months ended June 30, 2023, we recorded $195.4 million in royalty revenue related to the back royalties, $50.2 million of royalty revenue related to U.S. net sales of the Long-acting INVEGA products earned during the first quarter of 2023 and $75.7 million of royalty revenue related to worldwide net sales of the Long-acting INVEGA products earned during the second quarter of 2023. During the three and nine months ended September 30, 2023,March 31, 2024, Janssen’s worldwide net sales of the ~~Long-acting~~long-acting INVEGA products were ~~$1,029~~$1,056.0 million, ~~and $3,104.0 million, respectively,~~ as compared to ~~$1,031.0 million and $3,132.0~~$1,044.0 million during the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2023.

We expect royalty revenues from net sales of the ~~Long-acting~~long-acting INVEGA products to decrease in the near-term, as the royalty revenues related to net sales of INVEGA SUSTENNA are expected to end on August 20, 2024, ~~and~~which we anticipate will have a significant impact on our INVEGA SUSTENNA royalty revenues during 2024. In addition, each of INVEGA SUSTENNA and INVEGA TRINZA are currently subject to Paragraph IV litigation in response to companies seeking to market generic versions of such products. Increased competition from new products or generic versions of these products may lead to reduced unit sales of such products and increased pricing pressure. For a discussion of these legal proceedings, see Note 16, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q, and for information about risks relating to these legal proceedings, see “Part I, Item 1A—Risk Factors” in our Annual Report, and specifically the section entitled “We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

We receive a 15% royalty on worldwide net sales of VUMERITY manufactured and packaged by us, subject to increases in such royalty rate for VUMERITY manufactured and/or packaged by Biogen or its designees, in the period that the end-market sales of VUMERITY occur. We also recognize manufacturing revenue related to VUMERITY at cost plus 15%, upon making available bulk batches of VUMERITY to Biogen and, to the extent we package such product, then also when packaged batches of VUMERITY are made available to Biogen. Manufacturing revenue from VUMERITY ~~increased~~decreased by ~~$4.1~~$0.5 million ~~and $10.1 million during the three and nine months ended September 30, 2023, respectively, as compared to the three and nine months ended September 30, 2022. The increase~~ during the three months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three months ended ~~September 30, 2022,~~March 31, 2023. The decrease was primarily due to a reduction in the sales price, partially offset by increases in the number of ~~bulk~~packaged and ~~packaged~~bulk batches made available to Biogen. The ~~increase during~~reduction in the ~~nine months ended September 30, 2023, as compared~~sales price related to ~~the nine months ended September 30, 2022,~~our manufacturing revenue was primarily due to ~~an increase~~the removal of depreciation expense from the manufacturing cost base as the assets used to manufacture VUMERITY were classified as held for sale in the ~~number of bulk batches made available to Biogen, partially offset by a decrease in the number of packaged batches made available to Biogen.~~three months ended March 31, 2024. Royalty revenue related to VUMERITY increased by ~~$4.2 million and $2.6~~$2.9 million during the three ~~and nine~~ months ended ~~September 30, 2023, respectively,~~March 31, 2024, as compared to the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023. The ~~increases~~increase in royalty revenue ~~were~~was due to ~~increases~~an increase in end-market net sales of VUMERITY from ~~$137.8~~$108.2 million ~~and $402.6 million during the three and nine months ended September 30, 2022,~~

~~respectively, to $165.5 million and $419.9 million during the three and nine months ended September 30, 2023, respectively.~~

We recognize manufacturing revenue for RISPERDAL CONSTA at the point in time when RISPERDAL CONSTA has been fully manufactured, which is deemed to have occurred when the product is approved for shipment by both us and Janssen. We record royalty revenue, equal to 2.5% of Janssen’s end-market net sales, in the period that the end-market sales of RISPERDAL CONSTA occur. We expect revenues from RISPERDAL CONSTA to continue to decrease over time as patents covering RISPERDAL CONSTA expire in markets where end-market net sales of RISPERDAL CONSTA occur. The latest to expire patent covering RISPERDAL CONSTA expired in 2021 in the EU and in January 2023 in the U.S., and we are aware of potential generic and other competition to RISPERDAL CONSTA that may lead to reduced unit sales and increased pricing pressure. The increase in revenue from RISPERDAL CONSTA during the three months ended ~~September 30,~~March 31, 2023 ~~as compared~~ to ~~the three months ended September 30, 2022, was primarily due to an increase of $6.4~~$127.5 million in manufacturing revenue, partially offset by a decrease of $1.7 million in royalty revenue. The decrease in revenue from RISPERDAL CONSTA during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, was primarily due to decreases of $4.6 million in royalty revenue and $2.7 million in manufacturing revenue. The decreases in royalty revenue during the three and nine months ended September 30, 2023, as compared to the three and nine months ended September 30, 2022, were primarily due to expirations of the patents covering RISPERDAL CONSTA, as noted above. The increase in manufacturing revenue during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, was primarily due to an increase in the number of U.S. batches made available to Janssen. The decrease in manufacturing revenue during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, was primarily due to a decrease in the number of U.S. batches made available to Janssen and a 6% decrease in the rest of world average selling price of the product.March 31, 2024.

Costs and Expenses

Cost of Goods Manufactured and Sold


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,						September 30,						March 31,
(In millions)	2023		2022		Change		2023		2022		Change		2024		2023 (1)		Change
Cost of goods manufactured and sold	$	61.5	$	50.6	$	10.9	$	182.9	$	164.1	$	18.8	$	58.6	$	58.2	$	0.4

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The increase in cost of goods manufactured and sold during the three months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three months ended ~~September 30, 2022,~~March 31, 2023, was primarily due to ~~increases of $3.2 million, $3.2 million and $2.0 million in the cost of goods sold for ARISTADA and ARISTADA INITIO, LYBALVI and VIVITROL respectively, and~~ an increase of ~~$2.4 million in the cost of goods manufactured for RISPERDAL CONSTA, due to increases in the number of units manufactured and sold as discussed above.~~

The increase in cost of goods manufactured and sold during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, was primarily due to increases of $11.7 million, $5.9 million and $3.5$3.9 million in the cost of goods sold for VIVITROL, ~~LYBALVI and ARISTADA and ARISTADA INITIO, respectively,~~partially offset by decreases in the cost of goods manufactured for certain legacy products that we manufacture due to ~~increases~~a decrease in sales of such products. The increase in the ~~number~~cost of ~~units manufactured~~goods sold for ~~each product as discussed above.~~VIVITROL was primarily due to an increase in costs related to out-of-specification batches and investigation costs.

Research and Development Expenses

For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include fees for clinical and ~~non-clinical~~preclinical activities performed by contract research organizations, consulting fees, and costs related to laboratory services, the purchase of drug product materials and third-party manufacturing development activities. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, ~~with the exception of our oncology-related development programs,~~ internal R&D expenses are not tracked by individual program as they can benefit multiple development programs or our products or technologies in general. ~~We began tracking internal R&D expenses for our oncology-related development programs following the announcement of our intent to explore a separation of our oncology business.~~

The following table sets forth our external R&D expenses for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ relating to our then-current development programs and our internal R&D expenses, listed by the nature of such expenses:


	Three Months Ended							Nine Months Ended							Three Months Ended
	September 30,							September 30,							March 31,
(In millions)	2023		2022		Change			2023		2022		Change			2024		2023 (1)		Change
External R&D expenses:
Development programs:
nemvaleukin	$	20.4	$	21.6	$	(1.2	)	$	59.4	$	58.2	$	1.2
ALKS 2680															$	10.5	$	1.7	$	8.8
LYBALVI		4.2		6.5		(2.3	)		10.8		15.7		(4.9	)		5.0		3.3		1.7
ALKS 2680		5.5		3.0		2.5			17.8		7.5		10.3
Other external R&D expenses		13.6		15.7		(2.1	)		41.9		47.2		(5.3	)		8.8		14.4		(5.6	)
Total external R&D expenses		43.7		46.8		(3.1	)		129.9		128.6		1.3			24.3		19.4		4.9
Internal R&D expenses:
Employee-related		40.5		39.6		0.9			121.7		120.3		1.4			34.5		33.2		1.3
Occupancy		4.5		4.6		(0.1	)		13.6		13.3		0.3			3.0		2.9		0.1
Depreciation		2.4		3.1		(0.7	)		7.8		8.8		(1.0	)		1.4		2.3		(0.9	)
Other		6.1		6.4		(0.3	)		18.6		18.3		0.3			4.4		6.0		(1.6	)
Total internal R&D expenses		53.5		53.7		(0.2	)		161.7		160.7		1.0			43.3		44.4		(1.1	)
Research and development expenses	$	97.2	$	100.5	$	(3.3	)	$	291.6	$	289.3	$	2.3		$	67.6	$	63.8	$	3.8

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate our products under development based on the performance of such products in preclinical and/or clinical trials, our expectations regarding the likelihood of their regulatory approval and our view of their future potential commercial viability, among other factors.

The ~~decrease~~increase in expenses related to ~~nemvaleukin in~~ALKS 2680 during the three months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three months ended ~~September 30, 2022,~~March 31, 2023, was primarily due to ~~decreased~~an increase in spend ~~on the ARTISTRY-1 and ARTISTRY-2 studies, as activities~~ related to ~~these~~the advancement of the development program for the product, including completion of our phase 1b proof-of-concept study and activities to prepare for the initiation of our phase 2 clinical studies ~~wind down, partially offset by increased spend on~~for the ~~ARTISTRY-7 study. The~~product, the first of which was announced in April 2024 in patients with narcolepsy type 1, and the second of which we expect to initiate in patients with narcolepsy type 2 in the second half of 2024.The increase in expenses related to ~~nemvaleukin in~~LYBALVI during the ~~nine~~three months ended ~~September 30, 2023,~~March 31, 2024, as compared to the ~~nine~~three months ended ~~September 20, 2022,~~March 31, 2023, was primarily due to increased spend on the ~~ARTISTRY-7 study,~~pediatric studies

related to the product, partially offset by adecreased spend following the completion of the long-term safety and tolerability studies for the product. The decrease in spend on the ARTISTRY-1 and ARTISTRY-2 studies. For additional detail on the ARTISTRY development program for nemvaleukin, see the “Key Development Programs” section of this “Part I, Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q. The decreases inother external R&D expenses ~~related to LYBALVI in~~during the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three ~~and nine~~ months ended ~~September 30, 2022, were~~March 31, 2023, was primarily due to ~~decreased~~disciplined prioritization of R&D spend ~~on ongoing clinical studies. The increases in expenses related to ALKS 2680 in the three~~ and nine months ended September 30, 2023, as compared to the three and nine months ended September 30, 2022, were primarily due to increases in early-stage development expenses, including chemistry manufacturing and controls expenses and increased spend on a phase 1b proof-of-concept study, which was initiated in the second quarter of 2023.

~~In connection~~activities associated with ~~the planned separation of~~ our oncology business, we expect R&D expenses to decrease, as the continued development of nemvaleukin alfa and the discovery and development of our portfolio of novel, preclinical engineered cytokines would be transferred to, and become the responsibility of, Mural Oncology.research programs.

Selling, General and Administrative Expense


	Three Months Ended							Nine Months Ended						Three Months Ended
	September 30,							September 30,						March 31,
(In millions)	2023		2022		Change			2023		2022		Change		2024		2023 (1)		Change
Selling and marketing expense	$	114.8	$	96.9	$	17.9		$	371.2	$	288.4	$	82.8	$	125.6	$	118.5	$	7.1
General and administrative expense		54.6		55.9		(1.3	)		177.9		159.8		18.1		54.1		49.3		4.8
Selling, general and administrative expense	$	169.4	$	152.8	$	16.6		$	549.1	$	448.2	$	100.9	$	179.7	$	167.8	$	11.9

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The ~~increases~~increase in selling and marketing expense during the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three ~~and nine~~ months ended ~~September 30, 2022, were~~March 31, 2023, was primarily due to ~~increases~~a $4.7 million increase in marketing ~~expense of $11.9 million and $60.9 million, respectively, following the launch of~~spend related to the direct-to-consumer campaign for ~~LYBALVI and increases in employee-related~~LYBALVI. Employee-related expenses ~~of $6.5~~also increased by $2.0 million, ~~and $21.8 million, respectively,~~ primarily due to

~~a 6%~~ an increase in ~~sales and marketing headcount, increases~~share-based compensation expense related to the vesting of certain performance-based restricted stock unit awards, as previously discussed in ~~salaries, and increases~~Note 13, Share-based Compensation within the “Notes to Condensed Consolidated Financial Statements” in ~~employee travel as our in-person activities increased.~~this Form 10-Q.

The increase in general and administrative expense during the ~~nine~~three months ended ~~September 30, 2023,~~March 31, 2024, as compared to the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, was primarily due to an increase in employee-related expenses of ~~$11.3~~$4.8 million, and an increase in professional service fees of $7.0 million. The increases in employee-related expenses in the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, were primarily due to an increase in ~~salaries and benefits~~share-based compensation expense related to the vesting of certain performance-based restricted stock unit awards, as previously discussed in Note 13, Share-based Compensation within the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q, partially offset by a decrease in professional services fees of $1.9 million, primarily due to a 2% increase in average general and administrative headcount, increases in salaries and increased recruiting and other costs related to the planned separation of our oncology business. The increase in professional service fees in the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, was primarily due to increased spend on fees related to the planned separation of our oncology business and expenses related to activist shareholder activities.decreased legal expenses.

Other Income (Expense), Net


	Three Months Ended									Nine Months Ended									Three Months Ended
	September 30,									September 30,									March 31,
(In millions)	2023			2022			Change			2023			2022			Change			2024			2023			Change
Interest income	$	9.4		$	2.3		$	7.1		$	21.1		$	3.8		$	17.3		$	9.4		$	5.0		$	4.4
Interest expense		(6.0	)		(3.6	)		(2.4	)		(17.0	)		(8.3	)		(8.7	)		(6.0	)		(5.3	)		(0.7	)
Change in the fair value of contingent consideration		—			(3.6	)		3.6			—			(21.8	)		21.8
Other income (expense), net		0.1			(1.8	)		1.9			(0.4	)		2.4			(2.8	)		0.2			(0.1	)		0.3
Total other income (expense), net	$	3.5		$	(6.7	)	$	10.2		$	3.7		$	(23.9	)	$	27.6		$	3.6		$	(0.4	)	$	4.0

Interest income consists primarily of interest earned on our cash and available-for-sale investments. Interest expense consists of interest incurred on our 2026 Term Loans. The increases in interest income and interest expense in the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, as compared to the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, were primarily ~~due~~related to increases in interest rates, ~~over~~due to the ~~past twelve months, as we are in a~~ rising interest rate environment.

The changes in the fair value of the contingent consideration in the three and nine months ended September 30, 2023, as compared to the three and nine months ended September 30, 2022, were due to the determination that it was unlikely that we would collect any further contingent consideration proceeds under our agreements with Baudax, and accordingly, we reduced the fair value of the contingent consideration to zero, as discussed in Note 5, ~~Fair Value, in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q.~~

Income Tax ~~Benefit~~Provision


	Three Months Ended								Nine Months Ended
	September 30,								September 30,								March 31,
(In millions)	2023			2022			Change		2023			2022			Change		2024		2023 (1)		Change
Income tax benefit	$	(0.4	)	$	(3.4	)	$	3.0	$	(3.7	)	$	(15.6	)	$	11.9
Income tax provision																		8.0		0.7	$	7.3

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The income tax ~~benefit~~provision in the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 was primarily attributable to taxes on income earned in Ireland. The income tax provision in the three months ended March 31, 2023 was primarily due to U.S. federal and ~~2022 primarily related to enhanced FDII deductions arising from the capitalization of research and development expenses~~state taxes on income earned in ~~accordance with Section 174 of~~ the U.S. ~~Internal Revenue Code~~and the tax impact of ~~1986, as amended.~~employee equity activity.

On a quarterly basis, we reassess the valuation allowance on our deferred tax assets, weighing positive and negative evidence to determine the recoverability of such deferred tax assets. In the fourth quarter of 2022, we reassessed the valuation allowance and considered all positive and negative evidence, including our cumulative losses over the years ended December 31 ~~2022, 2021 and 2020 and concluded that we should maintain the valuation allowance on our Irish net operating losses and other deferred tax assets as of December 31, 2022.~~

We may release a significant portion of the valuation allowance upon completion of the planned separation of our oncology business; however, the release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, our level of profitability, revenue growth, clinical program progression, the successful completion of the planned separation of the oncology business and expectations regarding

~~future profitability. Our Irish deferred tax asset balance subject to the valuation allowance was approximately $245.8 million at December 31, 2022.~~

Liquidity and Financial Condition

Our financial condition is summarized as follows:


	September 30, 2023						December 31, 2022						March 31, 2024						December 31, 2023
(In millions)	U.S.		Ireland		Total		U.S.		Ireland		Total		U.S.		Ireland		Total		U.S.		Ireland		Total
Cash and cash equivalents	$	281.2	$	366.5	$	647.7	$	208.4	$	84.1	$	292.5	$	128.3	$	292.5	$	420.8	$	317.8	$	139.7	$	457.5
Investments—short-term		148.2		93.2		241.4		207.6		108.4		316.0		209.8		114.5		324.3		187.6		128.4		316.0
Investments—long-term		61.4		45.1		106.5		70.3		61.3		131.6		28.0		34.8		62.8		18.0		21.9		39.9
Total cash and investments	$	490.8	$	504.8	$	995.6	$	486.3	$	253.8	$	740.1	$	366.1	$	441.8	$	807.9	$	523.4	$	290.0	$	813.4
Outstanding borrowings—short and long-term	$	291.4	$	—	$	291.4	$	293.3	$	—	$	293.3	$	290.1	$	—	$	290.1	$	290.7	$	—	$	290.7

At ~~September 30, 2023~~March 31, 2024 our investments consisted of the following:


			Gross											Gross
	Amortized		Unrealized					Allowance for		Estimated		Amortized		Unrealized					Allowance for		Estimated
(In millions)	Cost		Gains		Losses			Credit Losses		Fair Value		Cost		Gains		Losses			Credit Losses		Fair Value
Investments—short-term available-for-sale	$	243.6	$	—	$	(2.2	)	$	—	$	241.4	$	324.6	$	0.5	$	(0.8	)	$	—	$	324.3
Investments—long-term available-for-sale		106.2		—		(1.5	)		—		104.7		61.6		—		(0.6	)		—		61.0
Investments—long-term held-to-maturity		1.8		—		—			—		1.8		1.8		—		—			—		1.8
Total	$	351.6	$	—	$	(3.7	)	$	—	$	347.9	$	388.0	$	0.5	$	(1.4	)	$	—	$	387.1

Sources and Uses of Cash

We generated ~~$294.1 million and $20.0~~$21.1 million of cash from operating activities and used $21.3 million of cash in operating activities during the ~~nine~~three months ended ~~September 30,~~March 31, 2024 and 2023, ~~and 2022,~~ respectively. We expect that our existing cash, cash equivalents and investments will be sufficient to finance our anticipated working capital and other cash requirements, such as capital expenditures and principal and interest payments on our ~~long‑term~~long-term debt, for at least the twelve months following the date from which our financial statements were issued. Subject to market conditions, interest rates and other factors, we may pursue opportunities to obtain additional financing in the future, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures. In addition, the 2026 Term Loans have an incremental facility capacity in an amount of $175.0 million, plus additional potential amounts, provided that we meet certain conditions, including a specified leverage ratio.

Our investment objectives are, first, to preserve capital and provide sufficient liquidity ~~and conserve capital~~to satisfy operating requirements and, second, to generate investment income. We mitigate credit risk in our cash reserves by maintaining a well-diversified portfolio that limits the amount of investment exposure as to institution, maturity, sector and investment type. However, the value of these securities may be adversely affected by the instability of the global financial markets, which could, in turn, adversely impact our financial position and our overall liquidity. Our available-for-sale investments consist primarily of short and long-term U.S. government and agency debt securities and corporate debt securities. ~~Our held-to-maturity investments consist of investments that are held as collateral under certain letters of credit related to certain of our lease agreements.~~

We classify ~~available‑for‑sale~~available-for-sale investments in an unrealized loss position that do not mature within twelve months as ~~long‑term~~long-term investments. We have the intent and ability to hold these investments until recovery, which may be at maturity, and it is ~~more‑likely‑than‑not~~more-likely-than-not that we would not be required to sell these securities before recovery of their amortized cost. ~~At September 30, 2023, we performed an analysis of our investments with unrealized losses for impairment and determined that they were not impaired.~~

~~In connection with the planned separation of our oncology business, we expect to make a cash contribution to Mural Oncology in the amount of $275.0 million upon completion of the separation.~~

We have no off-balance sheet arrangements that are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources in the next twelve months.

Information about our cash flows, by category, is presented in the accompanying consolidated statements of cash flows. The discussion of our cash flows that follows does not include the impact of any adjustments to remove discontinued operations and is stated on a total company consolidated basis. The following table summarizes our cash flows for the ~~nine~~three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Nine Months Ended September 30,

(In millions)

2023

2022

Cash and cash equivalents, beginning of period

$
292.5

$
337.5

Cash flows provided by operating activities

294.1

20.0

Cash flows provided by (used in) investing activities

74.3

(92.2
)
Cash flows used in financing activities

(13.2
)

(1.3
)
Cash and cash equivalents, end of period

$
647.7

$
264.0


	Three Months Ended March 31,
(In millions)	2024			2023
Cash and cash equivalents, beginning of period	$	457.5		$	292.5
Cash flows provided by (used in) operating activities		21.1			(21.3	)
Cash flows (used in) provided by investing activities		(39.9	)		72.8
Cash flows used in financing activities		(17.9	)		(22.6	)
Cash and cash equivalents, end of period	$	420.8		$	321.4

Operating Activities

Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income (loss) for non-cash operating items such as depreciation, amortization and share-based compensation and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.

Cash flows provided by operating activities for the ~~nine~~three months ended ~~September 30, 2023~~March 31, 2024 were ~~$294.1~~$21.1 million and primarily consisted of a net income of ~~$243.0~~$38.9 million adjusted for non-cash items, including share-based compensation of ~~$75.1~~$32.8 million, ~~and~~ depreciation and amortization of ~~$56.4~~$8.1 million and deferred income taxes of $7.5 million, partially offset by changes in working capital of ~~$34.3 million and deferred income taxes of $47.4~~$66.3 million. During the nine months ended September 30, 2023, net income included receipt of $195.4 million from Janssen, inclusive of $8.1 million in late-payment interest, related to 2022 U.S. net sales of the Long-acting INVEGA products following the successful outcome of the arbitration proceedings in respect of such products.

Cash flows ~~provided by~~used in operating activities for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 were ~~$20.0~~$21.3 million and primarily consisted of a net loss of ~~$130.0~~$41.8 million adjusted for non-cash items, including share-based compensation of ~~$67.8~~$22.6 million, depreciation and amortization of ~~$58.2 million, change in the fair value of contingent consideration of $21.8~~$18.7 million and changes in working capital of ~~$52.6~~$14.9 million, partially offset by deferred income taxes of ~~$54.1~~$36.1 million.

Investing Activities

Cash flows used in investing activities for the three months ended March 31, 2024 were primarily due to $32.0 million in net purchase of investments and the purchase of $8.3 million of property, plant and equipment. Cash flows provided by investing activities for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 were primarily due to ~~$105.4~~a $79.7 million increase in net sales of investments, offset by the purchase of ~~$31.0~~$6.9 million of property, plant and equipment. Cash flows used in investing activities for the nine months ended September 30, 2022 were primarily due to $65.8 million in net purchases of investments and the purchase of $28.2 million of property, plant and equipment.

Financing Activities

Cash flows used in financing activities for the ~~nine~~three months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ primarily related to ~~$26.1~~$28.3 million and ~~$17.9~~$24.7 million of employee taxes paid related to the net share settlement of equity awards, respectively, partially offset by ~~$15.1~~$11.2 million and ~~$18.8~~$2.9 million of cash that we received upon exercises of employee stock options, respectively.

Debt

At ~~September 30, 2023,~~March 31, 2024, the principal balance of our borrowings consisted of ~~$292.5~~$291.0 million outstanding under our 2026 Term Loans. See Note ~~11,~~12, Long-Term Debt, in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for further discussion of our 2026 Term Loans.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different conditions or using different assumptions.

See the “Critical Accounting Estimates” section in “Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report for a discussion of our critical accounting estimates.

New Accounting Standards

See the “New Accounting Pronouncements” section in Note 2, Summary of Significant Accounting Policies in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q for discussion of certain recent accounting standards applicable to us.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risks related to our investment portfolio, and the ways we manage such risks, are summarized in “Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report. We regularly review our marketable securities holdings and shift our investment holdings to those that best meet our investment objectives, which are to preserve capital, provide sufficient liquidity to satisfy operating requirements and generate investment income. Apart from such adjustments to our investment portfolio, there have been no material changes to our market risks since December 31, ~~2022,~~2023, and we do not anticipate any near-term changes in the nature of our market risk exposures or in our management’s objectives and strategies with respect to managing such exposures.

We are exposed to non-U.S. currency exchange risk related to manufacturing and royalty revenues that we receive on certain of our products, partially offset by certain operating costs arising from expenses and payables in connection with our Irish operations that are settled predominantly in Euro. These non-U.S. currency exchange rate risks are summarized in “Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report. There has been no material change in our assessment of our sensitivity to non-U.S. currency exchange rate risk since December 31, ~~2022.~~2023.

Item 4. Controls and Procedures

a) Evaluation of Disclosure Controls and Procedures

Our management has evaluated, with the participation of our ~~Chief Executive Officer~~principal executive officer and ~~Chief Financial Officer, evaluated~~interim principal financial officer, the effectiveness ~~of the design and operation~~ of our disclosure controls and procedures (as defined in ~~Rule~~Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of ~~September 30, 2023.~~March 31, 2024. Based onupon that evaluation, our ~~Chief Executive Officer~~principal executive officer and ~~Chief Financial Officer~~interim principal financial officer each concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective ~~as of September 30, 2023~~ to provide reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and ~~that~~(b) such information is accumulated and communicated to our management, including our ~~Chief Executive Officer~~principal executive officer and ~~Chief Financial Officer,~~interim principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

b) Change in Internal Control Over Financial Reporting

During the three months ended ~~September 30, 2023,~~March 31, 2024, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3734

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

For information regarding legal proceedings, see the discussion of legal proceedings in Note 16, Commitments and Contingent Liabilities in the “Notes to Condensed Consolidated Financial Statements” in this Form 10-Q, which discussion is incorporated into this Part II, Item 1 by reference.

Item 1A. Risk Factors

Disruptions at the FDA, the SEC and other government agencies caused by funding shortages could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized inFor a ~~timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and/or the planned separation~~discussion of our ~~oncology business.~~

~~The ability of the FDA to review and approve new products can be affected by a variety of~~risk factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuatedsee “Part I, Item 1A—Risk Factors” in ~~recent years as a result. In addition, government funding of the SEC and other government agencies on which~~ our ~~operations may rely is subject to the impacts of political events, which are inherently fluid and unpredictable.~~

Disruptions at the FDA and other agencies may slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA and the SEC to timely review and process our submissions, which could have a material adverse effect on our business and/or the planned separation of our oncology business.

Annual Report. There have been no ~~other~~ material changes from the risk factors disclosed in ~~“Part I, Item 1A—Risk Factors” of~~ our Annual ~~Report and “Part II, Item 1A—Risk Factors” of our Q1 Quarterly~~ Report. ~~The above risk factor should be read in conjunction with the risk factors disclosed in such reports.~~

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On ~~September 16, 2011,~~February 15, 2024, our board of directors authorized ~~the continuation of the Alkermes, Inc.~~a share repurchase program to repurchase ordinary shares of the Company in an aggregate amount of up to ~~$215.0~~$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time (the “2024 Repurchase Program”). The timing and amount of any share repurchases under the 2024 Repurchase Program will be based on a variety of factors, including but not limited to ongoing assessments of our needs, alternative investment opportunities, the market price of our ordinary shares and general market conditions. The 2024 Repurchase Program has no set expiration date and may be suspended or discontinued at ~~the discretion~~any time. The 2024 Repurchase Program terminates, and supersedes in its entirety, our prior share repurchase program authorized by our board of ~~management from time to time~~directors in ~~the open market or through privately negotiated transactions.~~September 2011. We did not purchase any shares under this program during the ~~nine~~three months ended ~~September 30, 2023. As of September 30, 2023, we had purchased a total of 8,866,342 shares under this program at an aggregate cost of $114.0 million.~~March 31, 2024.

During the three months ended ~~September 30, 2023,~~March 31, 2024, we acquired ~~26,943~~960,486 of our ordinary shares, at an average price of ~~$29.54~~$29.52 per share, to satisfy withholding tax obligations related to the vesting of employee equity awards.

Item 5. Other Information

During the three months ended ~~September 30, 2023, none of~~March 31, 2024, no officers (as defined in Rule 16a-1(f) under the ~~directors~~Exchange Act) or ~~executive officers~~directors of the Company adopted, ~~terminated~~modified or ~~materially modified~~terminated a ~~trading plan intended to comply with~~ Rule 10b5-1 trading arrangement or anon-Rule 10b5-1 trading ~~plan not intended to comply with Rule 10b5-1.~~arrangement (each such term as defined in Item 408 of Regulation S-K).

Item 6. Exhibits

The following exhibits are filed or furnished as part of this Form 10-Q:

EXHIBIT INDEX


Exhibit No.		Description of Exhibit
10.1 #*3.1 #		~~Confidential Settlement~~Memorandum and ~~License Agreement, dated August 29, 2023, by~~Articles of Association of Alkermes plc (as amended and ~~among Alkermes, Inc., Alkermes Pharma Ireland Limited and Teva Pharmaceuticals USA, Inc.~~
~~10.2 #§~~		~~Supply Agreement, dated September 26, 2003, by and between Acorda Therapeutics, Inc. and Elan Corporation, plc.~~
~~10.3 #§~~		~~Development and Supplemental Agreement between Elan Pharma International Limited and Acorda Therapeutics, Inc. dated January 14, 2011.~~restated on May 13, 2022).
31.1 #		Rule 13a-14(a)/15d-14(a) Certification.
31.2 #		Rule 13a-14(a)/15d-14(a) Certification.
32.1 ‡		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH #		Inline XBRL Taxonomy Extension Schema ~~Document.~~
~~101.CAL #~~		~~Inline XBRL Taxonomy Extension Calculation~~Document with Embedded Linkbase ~~Document.~~
~~101.LAB #~~		~~Inline XBRL Taxonomy Extension Label Linkbase Document.~~
~~101.PRE #~~		~~Inline XBRL Taxonomy Extension Presentation Linkbase Document.~~
~~101.DEF #~~		~~Inline XBRL Taxonomy Extension Definition Linkbase Document.~~Documents.
104 #		Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in ~~Exhibits~~Exhibit 101)

# Filed herewith.

‡ Furnished herewith.

~~† Indicates a management contract or any compensatory plan, contract or arrangement.~~

* Portions of this exhibit (indicated by “[**]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.36

§ Filed with this Form 10-Q solely for the purpose of transitioning this previously-filed exhibit, which is the subject of an expiring confidential treatment order, to the rules governing the filing of redacted exhibits under Regulation S-K Item 601(b)(10)(iv) pursuant to the SEC’s CF Disclosure Guidance: Topic 7. Portions of this exhibit (indicated by “[**]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	ALKERMES PLC

	(Registrant)


	By:	/s/ Richard F. Pops
		Richard F. Pops
		Chairman and Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ ~~Iain M. Brown~~Blair C. Jackson
		~~Iain M. Brown~~Blair C. Jackson
		~~Senior~~Executive Vice President, Chief ~~Financial~~Operating Officer
		(Interim Principal Financial ~~Officer and Principal Accounting~~ Officer)

Date: ~~October 25, 2023~~May 1, 2024

4037



Ireland		98-1007018
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary shares, $0.01 par value	ALKS	Nasdaq Global Select Market



Large accelerated filer ☒		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☐
		Emerging growth company ☐


	September 30, 2023			December 31, 2022			March 31, 2024			December 31, 2023
	(In thousands, except share and per share amounts)						(In thousands, except share and per share amounts)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	647,711		$	292,473		$	420,753		$	457,469
Receivables, net		337,697			287,967			315,848			332,477
Investments—short-term		241,439			315,992			324,295			316,022
Inventory		192,186			181,418			198,369			186,406
Contract assets		2,766			8,929			1,229			706
Prepaid expenses and other current assets		42,982			43,527			111,539			98,166
Assets held for sale								96,792			94,260
Total current assets		1,464,781			1,130,306			1,468,825			1,485,506
PROPERTY, PLANT AND EQUIPMENT, NET		327,517			325,361			224,590			226,943
RIGHT-OF-USE ASSETS								89,683			91,460
INVESTMENTS—LONG-TERM		106,431			131,610			62,782			39,887
RIGHT-OF-USE ASSETS		103,170			115,855
GOODWILL								83,027			83,027
INTANGIBLE ASSETS, NET		10,987			37,680			932			1,991
GOODWILL		92,873			92,873
DEFERRED TAX ASSETS		162,184			115,602			182,536			195,888
OTHER ASSETS		11,288			14,691			11,521			11,521
TOTAL ASSETS	$	2,279,231		$	1,963,978		$	2,123,896		$	2,136,223
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	243,263		$	220,089		$	205,854		$	240,561
Accrued sales discounts, allowances and reserves		238,467			252,115			240,877			263,641
Operating lease liabilities—short-term		15,058			15,722			5,910			5,746
Contract liabilities—short-term		3,319			6,816			3,336			2,730
Current portion of long-term debt		3,000			3,000			3,000			3,000
Liabilities related to discontinued operations								—			4,542
Total current liabilities		503,107			497,742			458,977			520,220
LONG-TERM DEBT		288,366			290,270			287,095			287,730
OPERATING LEASE LIABILITIES—LONG-TERM		78,552			89,829			74,102			75,709
OTHER LONG-TERM LIABILITIES		53,623			42,384			48,959			49,878
Total liabilities		923,648			920,225			869,133			933,537
COMMITMENTS AND CONTINGENT LIABILITIES (Note 16)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at September 30, 2023 and December 31, 2022, respectively		—			—
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 172,218,651 and 168,951,193 shares issued; 166,714,095 and 164,377,009 shares outstanding at September 30, 2023 and December 31, 2022, respectively		1,722			1,690
Treasury shares, at cost (5,504,556 and 4,574,184 shares at September 30, 2023 and December 31, 2022, respectively)		(186,942	)		(160,862	)
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023								—			—
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 175,734,220 and 172,569,051 shares issued; 169,184,516 and 166,979,833 shares outstanding at March 31, 2024 and December 31, 2023, respectively								1,757			1,726
Treasury shares, at cost (6,549,704 and 5,589,218 shares at March 31, 2024 and December 31, 2023, respectively)								(217,685	)		(189,336	)
Additional paid-in capital		3,003,184			2,913,099			2,780,992			2,736,934
Accumulated other comprehensive loss		(6,074	)		(10,889	)		(3,601	)		(3,110	)
Accumulated deficit		(1,456,307	)		(1,699,285	)		(1,306,700	)		(1,343,528	)
Total shareholders’ equity		1,355,583			1,043,753			1,254,763			1,202,686
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	2,279,231		$	1,963,978		$	2,123,896		$	2,136,223


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,						September 30,						March 31,
	2023			2022			2023			2022			2024			2023
	(In thousands, except per share amounts)												(In thousands, except per share amounts)
REVENUES:
Product sales, net	$	231,822		$	199,380		$	678,026		$	561,435		$	233,536		$	214,727
Manufacturing and royalty revenues		149,113			52,941			607,888			243,437			116,833			72,862
License revenue		—			—			—			2,000
Research and development revenue		3			36			16			249			3			6
Total revenues		380,938			252,357			1,285,930			807,121			350,372			287,595
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)		61,509			50,625			182,944			164,144			58,644			58,164
Research and development		97,140			100,430			291,565			289,256			67,611			63,770
Selling, general and administrative		169,446			152,777			549,181			448,206			179,749			167,833
Amortization of acquired intangible assets		8,995			9,166			26,693			27,198			1,059			8,800
Total expenses		337,090			312,998			1,050,383			928,804			307,063			298,567
OPERATING INCOME (LOSS)		43,848			(60,641	)		235,547			(121,683	)
OPERATING INCOME (LOSS) FROM CONTINUING OPERATIONS														43,309			(10,972	)
OTHER INCOME (EXPENSE), NET:
Interest income		9,370			2,239			21,105			3,708			9,399			4,966
Interest expense		(6,006	)		(3,552	)		(16,978	)		(8,271	)		(5,978	)		(5,288	)
Change in the fair value of contingent consideration		—			(3,553	)		—			(21,750	)
Other income (expense), net		149			(1,861	)		(415	)		2,380			182			(39	)
Total other income (expense), net		3,513			(6,727	)		3,712			(23,933	)		3,603			(361	)
INCOME (LOSS) BEFORE INCOME TAXES		47,361			(67,368	)		239,259			(145,616	)		46,912			(11,333	)
INCOME TAX BENEFIT		(397	)		(3,394	)		(3,719	)		(15,603	)
INCOME TAX PROVISION														7,964			717
NET INCOME (LOSS) FROM CONTINUING OPERATIONS														38,948			(12,050	)
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX														(2,120	)		(29,795	)
NET INCOME (LOSS)	$	47,758		$	(63,974	)	$	242,978		$	(130,013	)	$	36,828		$	(41,845	)

EARNINGS (LOSS) PER ORDINARY SHARE:
Basic	$	0.29		$	(0.39	)	$	1.46		$	(0.79	)
Diluted	$	0.28		$	(0.39	)	$	1.42		$	(0.79	)
Earnings (loss) per share from continuing operations - basic													$	0.23		$	(0.07	)
Loss per share from discontinued operations - basic													$	(0.01	)	$	(0.18	)
Earnings (loss) per share - basic													$	0.22		$	(0.25	)

Earnings (loss) per share from continuing operations - diluted													$	0.23		$	(0.07	)
Loss per share from discontinued operations - diluted													$	(0.01	)	$	(0.18	)
Earnings (loss) per share - diluted													$	0.21		$	(0.25	)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic		166,607			164,282			165,996			163,541			167,984			165,085
Diluted		171,903			164,282			170,981			163,541			172,981			165,085
COMPREHENSIVE INCOME (LOSS):
Net income (loss)	$	47,758		$	(63,974	)	$	242,978		$	(130,013	)	$	36,828		$	(41,845	)
Holding gain (loss), net of a tax provision (benefit) of $216, $(188), $803 and $(1,242), respectively		1,363			(2,349	)		4,815			(9,114	)
Holding (loss) gain, net of a tax (benefit) provision of $(75) and $488, respectively														(491	)		2,760
COMPREHENSIVE INCOME (LOSS)	$	49,121		$	(66,323	)	$	247,793		$	(139,127	)	$	36,337		$	(39,085	)



		Page No.
PART I - FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets — ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022~~2023	5
	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) — For the Three ~~and Nine~~ Months Ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~	6
	Condensed Consolidated Statements of Cash Flows — For the ~~Nine~~Three Months Ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~	7
	Condensed Consolidated Statements of Shareholders’ Equity — For the Three ~~and Nine~~ Months Ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~	8
	Notes to Condensed Consolidated Financial Statements	109
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2423
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3734
Item 4.	Controls and Procedures	3734

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	3835
Item 1A.	Risk Factors	3835
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3835
Item 5.	Other Information	3835
Item 6.	Exhibits	3936
Signatures		4037


	Ordinary Shares				Additional Paid-In		Accumulated Other Comprehensive			Accumulated			Treasury Stock
	Shares		Amount		Capital		Loss			Deficit			Shares			Amount			Total
	(In thousands, except share data)
BALANCE — December 31, 2022		168,951,193	$	1,690	$	2,913,099	$	(10,889	)	$	(1,699,285	)		(4,574,184	)	$	(160,862	)	$	1,043,753
Issuance of ordinary shares under employee stock plans		2,567,603		25		2,849		—			—			—			—			2,874
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards		—		—		—		—			—			(885,652	)		(24,744	)		(24,744	)
Share-based compensation		—		—		22,778		—			—			—			—			22,778
Unrealized gain on marketable securities, net of tax provision of $488		—		—		—		2,760			—			—			—			2,760
Net loss		—		—		—		—			(41,845	)		—			—			(41,845	)
BALANCE — March 31, 2023		171,518,796	$	1,715	$	2,938,726	$	(8,129	)	$	(1,741,130	)		(5,459,836	)	$	(185,606	)	$	1,005,576
Issuance of ordinary shares under employee stock plans		457,105		5		9,121		—			—			—			—			9,126
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards		—		—		—		—			—			(17,777	)		(540	)		(540	)
Share-based compensation		—		—		28,518		—			—			—			—			28,518
Unrealized gain on marketable securities, net of tax provision of $99		—		—		—		692			—			—			—			692
Net income		—		—		—		—			237,065			—			—			237,065
BALANCE — June 30, 2023		171,975,901	$	1,720	$	2,976,365	$	(7,437	)	$	(1,504,065	)		(5,477,613	)	$	(186,146	)	$	1,280,437
Issuance of ordinary shares under employee stock plans		242,750		2		3,111		—			—			—			—			3,113
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards		—		—		—		—			—			(26,943	)		(796	)		(796	)
Share-based compensation		—		—		23,708		—			—			—			—			23,708
Unrealized gain on marketable securities, net of tax provision of $216		—		—		—		1,363			—			—			—			1,363
Net income		—		—		—		—			47,758			—			—			47,758
BALANCE — September 30, 2023		172,218,651	$	1,722	$	3,003,184	$	(6,074	)	$	(1,456,307	)		(5,504,556	)	$	(186,942	)	$	1,355,583


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2023		2022		2023		2022
VIVITROL	$	99,305	$	96,534	$	298,035	$	277,493
ARISTADA and ARISTADA INITIO		81,834		75,719		244,320		222,826
LYBALVI		50,683		27,127		135,671		61,116
Total product sales, net	$	231,822	$	199,380	$	678,026	$	561,435


	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	76,109	$	76,109	$	—	$	410,910	$	410,910
VUMERITY		9,733		24,828		34,561		32,751		62,979		95,730
RISPERDAL CONSTA		14,732		151		14,883		30,049		957		31,006
Other		16,157		7,403		23,560		48,160		22,082		70,242
	$	40,622	$	108,491	$	149,113	$	110,960	$	496,928	$	607,888


	Three Months Ended September 30, 2022								Nine Months Ended September 30, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue			Total			Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	26,737		$	26,737		$	—	$	90,439	$	90,439
VUMERITY		5,584		20,666			26,250			22,629		60,386		83,015
RISPERDAL CONSTA		8,380		1,848			10,228			32,529		5,516		38,045
Other		3,265		(13,539	)		(10,274	)		26,472		5,466		31,938
	$	17,229	$	35,712		$	52,941		$	81,630	$	161,807	$	243,437


(In thousands)	November 15, 2023
ASSETS
Current Assets:
Cash and cash equivalents	$	275,000
Total current assets		275,000
Property, plant and equipment, net		10,096
Right-of-use assets		14,513
Goodwill		7,800
Deferred tax asset		1,799
Total assets	$	309,208
LIABILITIES
Current Liabilities
Operating lease liabilities—short-term	$	6,036
Total current liabilities		6,036
Operating lease liabilities—long-term		9,412
Total liabilities		15,448
Net assets transferred to Mural	$	293,760


	Three Months Ended
(In thousands)	March 31, 2023
OPERATING ACTIVITIES:
Depreciation	$	116
Share-based compensation expense		1,620
Right-of-use assets		3,066
Operating lease liabilities		(1,460	)

INVESTING ACTIVITIES:
Additions of property, plant and equipment	$	(100	)


	Three Months Ended March 31, 2024
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	62,673	$	62,673
VUMERITY		12,124		19,130		31,254
Other		17,906		5,000		22,906
	$	30,030	$	86,803	$	116,833


	Three Months Ended March 31, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	13,562	$	13,562
VUMERITY		12,649		16,225		28,874
Other		25,791		4,635		30,426
	$	38,440	$	34,422	$	72,862


(In thousands)	Contract Liabilities			Contract Liabilities
Contract liabilities at December 31, 2022	$	10,701
Contract liabilities at December 31, 2023				$	4,775
Additions		(931	)		—
Amounts recognized into revenue		(4,794	)		(208	)
Contract liabilities at September 30, 2023	$	4,976
Contract liabilities at March 31, 2024				$	4,567


	September 30,			March 31,
(In thousands)	2023			2024
Remaining 2023	$	4,103
2024		16,601		$	7,610
2025		16,848			10,227
2026		12,760			10,298
2027		9,505			9,508
2028					9,574
Thereafter		69,474			59,694
Total operating lease payments	$	129,291		$	106,911
Less: imputed interest		(35,681	)		(26,899	)
Total operating lease liabilities	$	93,610		$	80,012


(In thousands)
Balance, December 31, 2022	$	—
Restructuring charge		5,969
Amounts paid during the period:
Severance		(2,098	)
Benefits		(319	)
Outplacement services		(178	)
Balance, September 30, 2023	$	3,374

Indication(s)

Licensed Territory

Multiple sclerosis